Acitretin as Cancer Chemoprophylaxis in a Renal Transplant Recipient

Vandeghinste, N; Bersaques, J. De; Geerts, Marie; Kint, A

doi:10.1159/000247478

Cited by 24 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Experience with oral retinoids in renal transplant recipients has been limited because of theoretical immunopotentiating effects of the drug and concerns regarding graft rejection 5 . Two small uncontrolled studies using etretinate 6 , 7 and an anecdotal report of a single patient treated with acitretin 8 suggest a preventative effect on NMSC development in renal transplant recipients with no adverse effects on graft function. A more recent double‐blind, placebo controlled study using acitretin administered over 6 months showed a significant reduction in the number of new NMSC in the retinoid treated group 9 .…”

mentioning

confidence: 99%

Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin

1999

View full text Add to dashboard Cite

Renal transplant recipients have an increased risk of developing skin cancers, which are often multiple and aggressive. Frequently, these tumours develop on a background of widespread epidermal dysplasia. Systemic retinoids are known inhibitors of skin cancer but reports of their use in renal transplant patients are limited. We describe our experience using 0.3 mg/kg daily of acitretin in 16 patients over a 5-year period. Overall, there was a significant reduction in the number of new tumours excised in 12 of 16 patients during treatment compared with the same pretreatment interval. A significant chemoprophylactic effect was shown for up to 4 years of treatment. Patients with five or more tumours prior to acitretin benefited most. Two patients discontinued treatment because of side-effects and two patients developed hyperlipidaemia. Two patients with end-stage graft failure proceeded to haemodialysis. The introduction of low-dose acitretin proved to be a useful strategy in the long-term reduction of skin cancer in renal transplant recipients with multiple skin cancers and extensive epidermal dysplasia.

show abstract

mentioning

confidence: 99%

Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin

1999

View full text Add to dashboard Cite

show abstract

“…This results in a wide variety of infectious prob lems and in an increased incidence of malignancies. The frequency of developing malignancies is 100 times higher than in the control population and lies between 1.6 and 5.6% [14]. The number of tumors in the cyclosporinetreated group was significantly higher than in the group of patients with a conventional immunosuppression.…”

Section: Discussionmentioning

confidence: 81%

Tumors after Renal Transplantation

Schmidt

Stippel²,

Schmitz‐Rixen³

et al. 1996

Urol Int

View full text Add to dashboard Cite

The purpose of this retrospective study was to analyze the development of malignancies after renal transplantation. 633 renal graft recipients with an organ function longer than 1 year were followed up over a mean period of 67.6 ± 48.7 months. Only 12 recipients received grafts from living-related donors. 38 recipients (6.0%) exhibited cancer of either the skin, the genitourinary system, the bronchial system, the female breast, or the colon. All tumors were de novo malignancies. The number of patients developing a tumor was significantly higher in the cyclosporine-treated group than in patients with conventional immunosuppression. 15 patients died within a mean survival time of 7.7 ± 12.1 months. The frequency of disorders makes it necessary for organ transplant recipients to have routine examinations both before and at regular intervals after transplantation. This includes examination of the patient’s skin, native kidneys and cervical smears for females.

show abstract

“…Eight studies document the use of acitretin at doses ranging from 0.2 to 0.5 mg/kg per day and from 10 to 50 mg/day in 132 patients 65–72 . Harwood and colleagues conducted a retrospective study on 28 OTRs treated with low‐dose retinoids for 1 to 16 years (27 treated with acitretin, 1 with etretinate) 72 .…”

Section: Retinoids In Otrsmentioning

confidence: 99%